Callisto and Tauns Announce Capital and Business Alliance to Advance Medical Data and AI Utilization Infrastructure

Callisto Inc. (Headquarters: Shinjuku-ku, Tokyo; CEO: Chang-Hee Han (Calis), hereinafter "Callisto"), a developer of medical imaging data platforms for medical AI development and clinical research, and TAUNS Laboratories, Inc. (Headquarters: Izunokuni City, Shizuoka Prefecture; President and CEO: Masaki Nonaka, hereinafter "Tauns") have agreed to form a capital and business alliance aimed at building a medical data infrastructure and AI utilization platform. By combining Tauns’ medical institution and customer networks, commercialization infrastructure including regulatory and distribution systems, and computing resources with Callisto’s medical data technologies and resources, the two companies will accelerate their expansion into the pharmaceutical sector and overseas markets.

Background of the Alliance

To advance research and development in medical AI and drug discovery AI, as well as clinical studies, it is essential to appropriately collect, process, and integrate diverse medical data—including radiological and pathological images, clinical information such as electronic medical records, and specimen data including molecular information—into formats suitable for R&D. Additionally, there is a growing need to establish operational platforms that include computing resources, AI models, and AI analysis environments to securely and efficiently utilize this data.

Callisto has collaborated with medical institutions across Japan to build and provide medical imaging datasets, while also offering contract development and technical consulting services for drug discovery AI and medical AI. Tauns, as an in vitro diagnostic pharmaceutical manufacturer, has cultivated a robust network of medical institutions, along with extensive expertise in specimen outsourcing, customer engagement, and commercialization infrastructure covering regulatory affairs and distribution.

The two companies aim to combine their respective technological and business foundations to build a large-scale, multimodal medical data and AI utilization platform.

Objectives of the Alliance

Construction of a Multimodal Medical Data Infrastructure

The alliance will integrate medical images, clinical information including electronic medical records, specimen data, and biobank specimens into research-ready formats, while strictly complying with relevant laws and regulations and ensuring ethical standards and information security.

Development of an AI Utilization and Analysis Environment

The companies will establish an operational environment—including computing resources, AI models, and AI analysis platforms—to support advanced utilization of medical data and continuously generate value from it.

Acceleration of Pharmaceutical and International Expansion

By leveraging each other’s customer bases and commercialization know-how, and strengthening business development, marketing, and recruitment, the alliance will accelerate expansion into pharmaceutical applications and international markets.

Comment from Masaki Nonaka, President and CEO of TAUNS Laboratories, Inc.

“In our medium-term management plan, we have positioned the development of medical data and AI infrastructure as a key initiative.

We are delighted to partner with Callisto to co-create value through the utilization of medical data. Callisto possesses exceptional expertise and a strong track record in acquiring, processing, and analyzing medical data, making them a vital partner in advancing medical data utilization.

Moving forward, we will deepen our collaboration by leveraging our respective strengths to contribute to solving challenges in the medical field through effective data utilization.”

Comment from Chang-Hee Han (Calis), CEO of Callisto Inc.

“We are deeply grateful for the investment and recognition of our technological capabilities, medical data assets, and customer achievements in building a 'medical imaging data infrastructure' to support the era of medical AI and drug discovery AI.

By combining Tauns Group’s medical institution and customer networks, commercialization infrastructure including regulatory and distribution systems, and computing resources developed through specimen outsourcing with our own medical data technologies and resources, we will accelerate our expansion into the pharmaceutical sector and overseas markets.

Japan, one of the world’s most aged societies with universal health coverage, holds vast amounts of diverse, high-quality medical data—including radiological and pathological images, clinical information, and molecular specimen data. To date, we have collaborated with medical institutions across Japan to build medical imaging datasets, which we have provided to approximately 20 pharmaceutical companies, medical device manufacturers, medical AI firms, and academic institutions in Japan, the U.S., Europe, and South Korea.

Through this alliance, we will build a large-scale, multimodal medical data and AI analysis platform capable of cross-domain utilization of medical images, clinical information, molecular data, and biobank specimens, contributing globally to more accurate and earlier diagnosis and treatment, appropriate healthcare cost management, and the extension of healthy life expectancy.”

About TAUNS Laboratories, Inc.

TAUNS is one of Japan’s leading manufacturers of infectious disease diagnostic kits, engaged in the development, manufacturing, and sales of in vitro diagnostic pharmaceuticals and research reagents. With a strong focus on the infectious disease POCT field, the company has built long-standing trust and a solid customer base among medical institutions. In recent years, TAUNS has expanded into new business areas such as contract research and specimen outsourcing, and plans to further focus on building medical data and AI analysis platforms.

【Company Overview】

Company Name: TAUNS Laboratories, Inc. Business: Development, manufacturing, and sales of in vitro diagnostic pharmaceuticals, research reagents, and contract research Representative: President and CEO Masaki Nonaka Headquarters: 761-1 Kamijima, Izunokuni City, Shizuoka 410-2325, Japan Founded: June 1987

Website: https://www.tauns.co.jp

About Callisto Inc.

Callisto is a medical AI startup building medical imaging data infrastructure for medical AI and clinical research. Leveraging a network of Japanese medical institutions, the company constructs and provides datasets combining radiological and pathological images, clinical information, and molecular data. Callisto offers end-to-end services including data extraction, anonymization, case selection, standardization, annotation, and quality control, delivering datasets suitable for AI model development, external validation, imaging biomarker discovery, prognosis prediction, and treatment efficacy evaluation.

【Company Overview】

Company Name: Callisto Inc. Business: Building medical imaging data infrastructure for medical AI and clinical research; contract development and technical consulting for drug discovery AI and medical AI Representative: CEO Chang-Hee Han (Calis) Headquarters: 18F, Shinjuku Sumitomo Building, 2-6-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 171-0023, Japan Founded: June 2022

Website: https://callisto-ai.com

Recruitment Information

In conjunction with this capital and business alliance, both companies will strengthen recruitment to support business growth.

At Callisto, professionals from Corporate, Business, Technology, and Clinical divisions collaborate to build medical imaging data infrastructure.

Current key hiring positions include Sales, VP of Engineering, Medical AI Engineers, Software Engineers, and Dataset Managers.

We welcome individuals who are passionate about shaping the future of healthcare.

Recruitment Page: https://callisto-ai.com/recruit

For inquiries regarding data provision, dataset purchases, R&D outsourcing or consulting for drug discovery AI/medical AI, media interviews, speaking engagements, collaborations, investments, recruitment, or other questions, please contact us.